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High doses of Listeria monocytogenes overcome the ability of a normal mouse to control the infection, due to
massive bacterial replication. Treatment with an anti-interleukin 10 (IL-10) receptor monoclonal antibody
prevented the fatal course of infection with high doses of bacteria. This work shows that blocking the receptor
for IL-10 may have useful therapeutic applications.
Interleukin 10 (IL-10) is a major anti-inflammatory cytokine
required for the homeostasis of the host organism subjected to
continuous exposure to microorganisms (9). However, IL-10
may lead to ineffective control of microbial infections and,
therefore, blocking its activity could prove to be of beneficial
value. Listeria monocytogenes is a facultative intracellular bac-
terium whose proliferation in vivo is controlled by CD81 and
CD41 cells secreting gamma interferon (IFN-g) (11). These
protective mechanisms can be overcome by increasing the dose
of the infecting inoculum, leading to fatal infections. The
mechanisms underlying the inability to control the infection
with high bacterial numbers have never been analyzed but
could be related to the mobilization of an insufficient number
of effector cells or cytokines. Alternatively, high bacterial doses
may trigger inhibitory mechanisms leading to down-modula-
tion of the protective immune response. Early in infection,
macrophages produce a variety of cytokines, including IL-12
and IL-10, in response to bacterial products. The latter cyto-
kine has a suppressive role in the protective immune response
in murine listeriosis and is, therefore, a candidate to explain
the lethality from infections by high doses of listeriae. Previous
studies have indeed shown that antibodies specific for IL-10
can transiently reduce listerial loads in infected mice (12) and
that IL-10 gene-deficient mice are more resistant to infection
(1). However, lethality from listeriosis in adult mice was not
reverted by an IL-10-specific monoclonal antibody (4). The
goal of our study was, therefore, to evaluate the effects of a
recently produced blocking monoclonal antibody specific for
the IL-10 receptor (IL-10R) (8) during listeriosis induced by
injecting different doses of L. monocytogenes, namely the an-
tibody’s ability to revert the lethality following infection with
high doses of bacteria.
BALB/c mice were injected intravenously with 3.7 3 104,
1.0 3 104, or 4.3 3 103 CFU of L. monocytogenes strain EGD,
which had been maintained in frozen stocks prepared from
cultures initiated after in vivo passage of the strain. To block
the effect of IL-10 during the course of the infection, mice were
injected intraperitoneally with an anti-IL-10R monoclonal an-
tibody (produced with the 1B1.2 hybridoma cell line [8] sup-
plied by K. Moore, DNAX, Palo Alto, Calif.) or with rat
immunoglobulin as a control (1 mg 24 h before infection and
0.2 mg at days 1 and 3 after infection). The amounts of anti-
body injected were previously titrated in vivo against the effect
on listerial multiplication. Viable bacteria (CFU) were quan-
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FIG. 1. Administration of an IL-10R-specific monoclonal antibody
protects against the lethal course of infection by high doses of L.
monocytogenes. Groups of five BALB/c mice were infected intrave-
nously with the indicated numbers of bacteria and treated with either
anti-IL-10R antibodies (closed symbols) or nonimmune rat immuno-
globulin (open symbols). Bacterial counts were performed for the
livers and spleens of the infected animals at the indicated time points
postinfection. Each point represents the log10 CFU value from one
animal, and the horizontal lines represent the geometric means. The =
represents the death of two animals.
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tified in organ homogenates by plating 10-fold serial dilutions
on solid media. The results are shown in Fig. 1. The bacterial
loads found in either the livers or spleens of mice treated with
anti-IL-10R antibodies were always lower than those in control
mice. Mice infected with a lethal inoculum of Listeria and
treated with anti-IL-10R not only survived but were also able
to control the bacterial multiplication, whereas no mice sur-
vived beyond day 4 when only injected with the higher dose of
Listeria. Additionally, the bacterial loads in 1B1.2-treated mice
were very similar at day 5, irrespective of the initial inoculum
dose.
Samples from infected livers were studied by histological
analysis (Fig. 2). On day 3, decreases in the number and size of
granulomatous lesions were found in the animals treated with
anti-IL-10R antibodies (Fig. 2A) compared to controls (Fig.
2B). After 4 days of infection, the control mice showed severe
liver injury (Fig. 2D), with a high number of granulomatous
lesions and an extensive inflammatory infiltrate, and often with
areas of necrosis and microcalcifications. In treated mice, only
a small number of inflammatory foci were found in the livers
after 5 days of infection (Fig. 2C).
The mechanisms whereby IL-10 hinders the development of
protective immunity in listeriosis are not yet clear. We found
that the anti-IL-10R monoclonal antibody induced a slight
improvement in the immune response, as measured by in-
creased IFN-g secretion upon specific stimulation of spleno-
cytes. Mice were sublethally infected, the bacterial loads were
determined, and the spleen cells were stimulated in vitro as
described elsewhere (10), following stimulation with heat-
killed Listeria as antigen (20 3 106 bacilli/ml). The bacterial
counts in the spleens at 2, 4, and 7 days postinfection were
5.16 6 0.44, 4.72 6 0.39, and 2.51 6 1.23 log10 CFU, respec-
tively, in the control animals and 4.63 6 0.34, 4.10 6 0.23, and
1.59 6 0.93 log10 CFU, respectively, in the animals that re-
ceived the anti-IL-10R antibodies. At the same time points,
spleen cell supernatants from the control group had 2.9 6 0.5,
11.7 6 4.7, and 34.8 6 12.5 ng of IFN-g per ml, respectively,
whereas those from anti-IL-10R antibody-treated animals had
2.8 6 0.8, 7.1 6 3.2, and 59.4 6 20.5 ng of IFN-g per ml,
respectively. The slight enhancement of the IFN-g response
was apparent late in infection (statistically significant differ-
ences were only present at day 7; P , 0.05); this was later than
the protection afforded by anti-IL-10R against bacterial mul-
tiplication (P , 0.05 at day 2 and P , 0.01 at day 4). Therefore,
the deleterious effect of IL-10 may relate to the inhibition of
the innate response by IL-10 produced early in the infection by
macrophages (2), namely the induction of cytokines or co-
stimulatory molecules that are involved in protective immunity
and priming of T cells for IFN-g production. We could not find
any improvement in leukocyte recruitment, namely of neutro-
phils, or on phagocyte function (e.g., nitric oxide production)
after treating listeria-infected mice with the anti-IL-10R anti-
body (data not shown). However, additional studies should be
carried out to understand the role of IL-10 in listeriosis.
The role of IL-10 described here regarding massive infec-
tions with L. monocytogenes presumably may be extended to
other infections, as was recently done for Klebsiella (13). How-
ever, in other models of infection such as Toxoplasma gondii
and plasmodium infections, interference with IL-10 signaling
led to exacerbated inflammatory responses and, eventually,
death of the animals (3, 6). In contrast, IL-10 has counterpro-
tective activities in mycobacterial infections (5, 7). Therefore,
the neutralization of the receptor for IL-10 may be a promising
approach as an adjunct therapy for severe septicemias and in
chronic infections such as mycobacteriosis, namely in human
patients, but its use must be avoided in other infections where
the anti-inflammatory effects of IL-10 are of importance.
We are indebted to J. Pedrosa and C. Oliveira for helpful technical
assistance and to K. Moore and DNAX for the gift of the 1B1.2
hybridoma cell line.
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